Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 6, 2003, Pages 32-38

  Thomas, Anne L ^a   Morgan, Bruno ^b   Drevs, Joachim ^b   Unger, Clemens ^b   Wiedenmann, Bertram ^b   Vanhoefer, Udo ^b   Laurent, Dirk ^b   Dugan, Margaret ^b   Steward, William P ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ATAXIA; CLINICAL TRIAL; COLORECTAL CANCER; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER METASTASIS; MOUSE; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR XENOGRAFT; VERTIGO; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DRUG SCREENING ASSAYS, ANTITUMOR; GADOLINIUM; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; PHTHALAZINES; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 0038176090     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00123-4     Document Type: Review

References (27)

1. Shibuya M, Yamaguchi S, Yamane A, et al: Nucleotide sequence and expression of a novel human receptor-type tyrosine gene (flt) closely related to the fms family. Oncogene 5:519-524, 1990
2. Terman BI, Carrion ME, Kovacs E, et al: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677-1683, 1991
3. Senger RD, Van de Water L, Brown LF, et al: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324, 1993
4. Ingber D, Fujita T, Kishimoto S, et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-557, 1990
5. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
6. Ellis LM, Liu W, Wilson M: Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation. Surgery 120:871-878, 1996
7. Konno H, Abe J, Kaneko T, et al: Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn J Cancer Res 92:516-523, 2001
8. Taylor JS, Tofts PS, Port R, et al: MR imaging of tumor microcirculation: Promise for the new millennium. J Magn Reson Imaging 10:903-907, 1999
9. Larsson HB, Stubgaard M, Sondergaard L, et al: In vivo quantification of the unidirectional influx constant for Gd-DTPA diffusion across the myocardial capillaries with MR imaging. J Magn Reson Imaging 4:433-440, 1994
10. Larsson HB, Fritz-Hansen T, Rostrup E, et al: Myocardial perfusion modelling using MRI. Magn. Reson Med 35:716-726, 1996
11. Morgan B, Jivan A, Horsfield MA, et al: Validation of a snapshot FLASH protocol for rapid assessment of contrast enhancement to monitor tumor therapy. Proc Intl Soc Mag Reson Med 8:1036, 2000 (abstr)
12. Jivan A, Horsfield MA, Moody AR, et al: Dynamic T1 measurement using snapshot-FLASH MRI. J Magn Reson 127:65-72, 1997
13. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000
14. Drevs J, Hofmann I, Hugenschmidt H, et al: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819-4824, 2000
15. Siemeister G, Martiny-Baron G, Marme D: The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities. Cancer Metastasis Rev 17:241-248, 1998
16. Thomas A, Morgan B, Drevs J, et al: Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 20:71a, 2001 (abstr 279)
17. Thomas A, Morgan B, Rowark G, et al: Phase I study of the oral VEGF-receptor inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer. Clin Cancer Res 7:3662, 2001 (abstr 48)
18. George D, Jonasch E, Hart L, et al: A phase I, dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced renal cell or prostate carcinomas. Clin Cancer Res 7:3764S, 2001 (abstr 548)
19. Friedman HS, Yung WA, Jackson E, et al: A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGF-R TK inhibitor in patients with recurrent GBM. Clin Cancer Res 7:3665S, 2001 (abstr 58)
20. Drevs J, Mross K, Fuxius S: A phase I dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor-inhibitor PTK787/ZK222584 (PTK/ZK) in patients with liver metastasis of advanced cancer. Proc Am Soc Clin Oncol 20:100a, 2001 (abstr 398)
21. Schnidermann MA: Mouse to man: Statistical problems in bringing a drug to clinical trial. Fifth Berkerley Symposium on Mathematical Statistical Problems, University of California 855, 1967
22. Drevs J, Schmidt-Gersbach C, Mross K, et al: VEGF and sTIE-2 are useful blood markers for hypoxia under antiangiogenic treatment with a specific VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in cancer patients. Clin Cancer Res 7:3712S, 2001 (abstr 291)
23. Drevs J, Muller-Driver R, Wittig C, et al: PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62:4015-4022, 2002
24. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
25. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
26. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
27. Steward W, Wiedenmann B, Rosewicz S, et al: Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 with chemotherapy (oxaliplatin/5-FU/leucovorin) in patients with advanced colorectal cancer. Clin Cancer Res 7:3663S, 2001 (abstr 50)